WO2003082256A3 - Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 - Google Patents

Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 Download PDF

Info

Publication number
WO2003082256A3
WO2003082256A3 PCT/FR2003/000964 FR0300964W WO03082256A3 WO 2003082256 A3 WO2003082256 A3 WO 2003082256A3 FR 0300964 W FR0300964 W FR 0300964W WO 03082256 A3 WO03082256 A3 WO 03082256A3
Authority
WO
WIPO (PCT)
Prior art keywords
useful
receptor antagonist
sexual
performances
cannabinoid receptor
Prior art date
Application number
PCT/FR2003/000964
Other languages
English (en)
Other versions
WO2003082256A2 (fr
Inventor
Michele Arnone
Original Assignee
Sanofi Synthelabo
Michele Arnone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Michele Arnone filed Critical Sanofi Synthelabo
Priority to AU2003244722A priority Critical patent/AU2003244722A1/en
Publication of WO2003082256A2 publication Critical patent/WO2003082256A2/fr
Publication of WO2003082256A3 publication Critical patent/WO2003082256A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Utilisation d'un antagoniste des récepteurs aux cannabinoïdes CB 1 en particulier le rimonabant et le N-pipéridino-5-(4-bromophényl)-1-(2,4-dichlorophényl)-4­éthylpyrazole-3-carboxamide ainsi que leurs sels et leurs solvats pharmaceutiquement acceptables pour la préparation de médicaments utiles pour traiter les dysfonctionnements des comportements sexuels et/ou améliorer les performances sexuelles.
PCT/FR2003/000964 2002-03-28 2003-03-27 Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 WO2003082256A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003244722A AU2003244722A1 (en) 2002-03-28 2003-03-27 Use of a cb1 cannabinoid receptor antagonist for producing medicaments which are useful for treating sexual behaviour problems and/or for improving sexual performances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/03961 2002-03-28
FR0203961A FR2837706A1 (fr) 2002-03-28 2002-03-28 Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles

Publications (2)

Publication Number Publication Date
WO2003082256A2 WO2003082256A2 (fr) 2003-10-09
WO2003082256A3 true WO2003082256A3 (fr) 2004-04-01

Family

ID=27839313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000964 WO2003082256A2 (fr) 2002-03-28 2003-03-27 Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1

Country Status (3)

Country Link
AU (1) AU2003244722A1 (fr)
FR (1) FR2837706A1 (fr)
WO (1) WO2003082256A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
EP1492784A4 (fr) 2002-03-28 2006-03-29 Merck & Co Inc 2,3-diphenyl-pyridines substituees
EP1499306A4 (fr) 2002-04-12 2007-03-28 Merck & Co Inc Amides bicycliques
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (fr) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Amides substitues
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1574211A1 (fr) 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
EP1886684A1 (fr) * 2006-08-07 2008-02-13 Ratiopharm GmbH Composition pharmaceutique comprenant du rimonabant
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656354A1 (fr) * 1993-12-02 1995-06-07 Sanofi N-pipéridino-3-pyrazolecarboxamide substitué
WO2000046209A1 (fr) * 1999-02-01 2000-08-10 Sanofi-Synthelabo Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
WO2001064633A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
WO2002053140A2 (fr) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company Nouvelles combinaisons medicamenteuses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656354A1 (fr) * 1993-12-02 1995-06-07 Sanofi N-pipéridino-3-pyrazolecarboxamide substitué
WO2000046209A1 (fr) * 1999-02-01 2000-08-10 Sanofi-Synthelabo Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
WO2001064633A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
WO2002053140A2 (fr) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company Nouvelles combinaisons medicamenteuses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DALTERIO S ET AL: "Cannabinoids inhibit testosterone secretion by mouse testes in vitro.", SCIENCE. UNITED STATES 24 JUN 1977, vol. 196, no. 4297, 24 June 1977 (1977-06-24), pages 1472 - 1473, XP008012074, ISSN: 0036-8075 *
FERRARI F ET AL: "INHIBITORY EFFECTS OF THE CANNABINOID AGAINST HU 210 ON RAT SEXUAL BEHAVIOUR", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 69, no. 4/5, 1 June 2000 (2000-06-01), pages 547 - 554, XP001128190, ISSN: 0031-9384 *
MANI S K ET AL: "PROGESTERONE RECEPTOR AND DOPAMINE RECEPTORS ARE REQUIRED IN DELTA9-TETRAHYDROCANNABINOL MODULATION OF SEXUAL RECEPTIVITY IN FEMALE RATS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 January 2001 (2001-01-30), pages 1249 - 1254, XP001128188, ISSN: 0027-8424 *
OTTANI A ET AL: "NEUROLEPTIC-LIKE PROFILE OF THE CANNABINOID AGONIST, HU 210, ON RODENT BEHAVIOURAL MODELS", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 26, no. 1, 2002, pages 91 - 96, XP001133701, ISSN: 0278-5846 *
SODERSTROM K ET AL: "BEHAVIORAL, PHARMACOLOGICAL, AND MOLECULAR CHARACTERIZATION OF AN AMPHIBIAN CANNABINOID RECEPTOR", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 75, no. 1, 2000, pages 413 - 423, XP001128191, ISSN: 0022-3042 *
STELLA N: "HOW MIGHT CANNABINOIDS INFLUENCE SEXUAL BEHAVIOR?", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 January 2001 (2001-01-30), pages 793 - 795, XP001128187, ISSN: 0027-8424 *
WENGER T ET AL: "THE EFFECTS OF CANNABINOIDS ON THE REGULATION OF REPRODUCTION", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 65, no. 6/7, 1999, pages 695 - 701, XP001128193, ISSN: 0024-3205 *

Also Published As

Publication number Publication date
WO2003082256A2 (fr) 2003-10-09
AU2003244722A1 (en) 2003-10-13
FR2837706A1 (fr) 2003-10-03

Similar Documents

Publication Publication Date Title
WO2001058450A3 (fr) Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
WO2003082256A3 (fr) Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1
HUP0201278A2 (hu) Pirazolkarbonsav-amid-származék, előállítása, az azt tartalmazó gyógyszerkészítmények és intermedierjei
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
WO2002028346A3 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite
WO2005121097A3 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
WO2007012661A8 (fr) Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1
WO2004050040A3 (fr) Composition pharmaceutique de 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine et utilisations
IL176547A0 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
MXPA04004741A (es) Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial alcanabinoide1.
HK1072052A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
WO2005084652A3 (fr) Utilisation d'antagonistes du recepteur cb1 pour preparer une composition utile pour le traitement des maladies hepatiques
LU92238I2 (fr) 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one ou l'un de sls physiologiquement acceptables. autre formulation du composé chimiqu e:1-(4-Chlorophenyl)4-morpholino-imidazolin-2-one
WO2004111047A3 (fr) Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
MEP10608A (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
BG107046A (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AU2002343523A1 (en) Methods of using 279, a human g protein-coupled receptor
MX2007004483A (es) Metodo y productos intermediarios para la preparacion de derivados de n-(1-benzhidril-azetidin-3-il)-n- fenilmetilsulfonamida.
IL166303A0 (en) Crystal modification of 2-Ä2-(1-chloro-cyclopropyl)-3-(2-chlorophenyl)-2-hydroxy-propylÜ-2,4-dihydro-3h-1,2,4-triazole-3-thions
HK1040078B (zh) 3-(2，4-二氯苄基)-2-甲基-n-(戊璜酰基)-3h-苯並咪唑-5-羧酰胺的晶形
WO2001079154A3 (fr) Synthese de midodrine hcl a partir du nouveau produit intermediaire 1-(2',5'-dimethoxyphenyl)-2-azidoethanone
NO20063299L (no) Syntese av en polymorf av 4-amino-5-klor-2-metoksy-N-(1-azabisyklo[3.3.1]non-4-yl)benzamidhydrokloridhydrat
WO2006000009A3 (fr) Oxyde ferrique lamellaire
DE60209708D1 (de) Azol- oder triazol-derivate, verfahren zu deren herstellung und ihre verwendung als fungizide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP